Teleflex Announces Real-World Clinical Data Presentations of the UroLift System

Teleflex

WAYNE, PA — Teleflex Incorporated (NYSE: TFX) announced that new data from real-world clinical studies of the UroLift® System for men with benign prostatic hyperplasia (BPH) will be presented at the 36th European Association of Urology (EAU) 2021 Annual Congress taking place virtually July 8-12.

There is increasing interest in the role of Real-World Data (RWD) to supplement data from randomized controlled trials (RCTs) and demonstrate effectiveness in the broad population of patients and health care providers in the real world. Teleflex has invested significantly in RWD and these study results will provide new insights about men treated with the Prostatic Urethral Lift (PUL) procedure using the UroLift System.

Presentations of the UroLift System at EAU include (all times are local Central European Summer Time (CEST)):

READ:  UGI Corporation to Hold 1QFY22 Earnings Conference Call

Thursday, July 8:

  • “Prostatic Urethral Lift (PUL) in Retention Patients: 12-month Outcomes from Real-World and PULSAR Studies” will be presented by Mark Rochester+, M.D., Norwich University, at 9:00 a.m. CEST (3:00 a.m. EDT) in Virtual Room 9.
  • “Real-World Predictors of Durability After Prostatic Urethral Lift (PUL)” will be presented by Oliver Kayes+, M.D., Leeds, at 9:00 a.m. CEST (3:00 a.m. EDT) in Virtual Room 9.
  • “Prostatic Urethral Lift (PUL) Effectiveness in Real-World Subjects with Obstructive Median Lobes” will be presented by Neil Barber+, M.D., Camberley, at 9:00 a.m. CEST (3:00 a.m. EDT) in Virtual Room 9.

Friday, July 9:

  • Analysis of Real-World Healthcare Data of Outcomes of Interventional Procedures in BPH” will be presented by Steven Kaplan, M.D., Mount Sinai, at 10:00 a.m. CEST (4:00 a.m. EDT) in Virtual Room 3.
READ:  AMETEK Announces Fourth Quarter 2021 Earnings Call

Teleflex state that the UroLift® System is a minimally invasive treatment for lower urinary tract symptoms due to benign prostatic hyperplasia (BPH). It is indicated for the treatment of symptoms of an enlarged prostate up to 100cc in men 45* years or older (*50 years outside US).

Thanks for visiting! MyChesCo brings reliable information and resources to Chester County, Pennsylvania. Please consider supporting us in our efforts. Your generous donation will help us continue this work and keep it free of charge. Show your support today by clicking here and becoming a patron.